Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Core Viewpoint - Ovid Therapeutics Inc. has appointed Dr. Stelios Papadopoulos to its Board of Directors, which is seen as a strategic move to enhance the company's growth and innovation in developing small-molecule medicines for neurological and psychiatric conditions [1][2]. Company Overview - Ovid Therapeutics is a biopharmaceutical company focused on creating novel medicines for brain conditions with significant unmet needs, advancing a pipeline of targeted small molecule candidates [4]. - The company is developing several key programs, including OV329 for treatment-resistant seizures, OV350 targeting multiple CNS disorders, and OV888/GV101 for neurovascular and neuro-inflammatory conditions [4]. Leadership and Expertise - Dr. Stelios Papadopoulos is recognized as a pioneering force in biotechnology, with over four decades of experience, including roles in investment banking and equity research [2]. - His leadership and strategic vision are expected to be instrumental in propelling Ovid forward, particularly in the context of its advancing pipeline and the potential for transformative medicines [2][3]. Strategic Importance - The appointment of Dr. Papadopoulos comes at a critical time for Ovid, as the company aims to deliver significant advancements in the treatment of neurological and psychiatric diseases [2]. - His involvement is anticipated to enhance Ovid's capabilities in bridging scientific discovery with financial strategy, which is crucial for the company's growth [2].